Sarah Ford | August 11, 2014
Compound Restores Memory Function in Mouse Alzheimer’s Model
Researchers from Yale School of Medicine have discovered a promising new drug compound that reverses some Alzheimer’s effects on memory in mice.
The work directly stems from a 2008-11 BrightFocus grant to Paul Lombroso, MD, who’s on the Yale neurobiology and psychiatry faculty and directs its Laboratory of Molecular Neurobiology. He is senior author of a report published in PLoS Biology August 5.
They found that a protein drug compound, known as TC-2153, blocks the Alzheimer’s disease linked effects of another protein called striatal-enriched tyrosine phosphatase (STEP). At high levels, STEP prevents synaptic strengthening in the brain—something vital to memory function.
It’s actually one of several breakthroughs tied to this BrightFocus grant, which included 2000 Nobel Laureate Paul Greengard, PhD, of Rockefeller University, as coinvestigator. Four years ago…
Get Resources and Insights Straight To Your Inbox
Explore More Articles
Is Your Company Ready to Launch a Scholarship Program This Fall?
Here’s What You Need to Know Now is the ideal time for companies to partner with a scholarship administrator – here’s why and how to…
How Much Money Does Your Company’s Emergency Assistance Fund Actually Need?
Setting up an Employee Assistance Fund (EAF) is one of the most practical ways to support employees during times of crisis. One of the first…
Get Resources and Insights Straight To Your Inbox
Receive our monthly/bi-monthly newsletter filled with information about causes, nonprofit impact, and topics important for corporate social responsibility and employee engagement professionals, including disaster response, workplace giving, matching gifts, employee assistance funds, volunteering, scholarship award program management, grantmaking, and other philanthropic initiatives.